Acacia Aghast As FDA Says No To Barhemsys
The UK company has been stunned by a complete response letter for its nausea and vomiting therapy which relates to problems at its contract manufacturer but is not linked to the data package. Despite the setback, Acacia is sticking to a first-half 2019 launch plan.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Complete response letter for Acacia’s Barhemsys is only rain on Oct. 5 approval parade.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.